SAINT LAURENT, Quebec, April 24, 2014 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX: IGXT) (“IntelGenx”), a Canadian drug delivery company focusing on oral drug delivery, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (“RedHill”), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage proprietary drugs, today reported that the U.S. Food and Drug Administration (“FDA”) acknowledged receipt of their response to the Complete Response Letter (“CRL”) for the VersaFilm™ Oral Film Product New Drug Application (“NDA”) and has requested further clarifications. The VersaFilm™ Oral Film Product is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines.
Help employers find you! Check out all the jobs and post your resume.
